Skip to main content

Table 3 Comparison of the two groups of patients in terms of intraoperative, postoperative and histopathological results

From: Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma

  Bilirubin
≤75 μmol/L
(n = 82)
Bilirubin
> 75 μmol/L
(n = 8)
P value
Blood loss (L) 1.4 (0.3–20) 3.12 (1.4–6.0) 0.008a
Blood replacement (L) 0.0 (0.0–13.8) 2.45 (0.6–4.3) < 0.001a
Blood transfusion 34 (42.0%) 8 (100%) 0.011a
Operation time (min) 674.0 (222–1290) 797.0 (514–960) 0.156
Type of resection    0.558
 Right hepatectomy 5 (6.1%) 1 (12.5%)  
 Right extended hepatectomy 3 (3.7%) 0 (0%)  
 Left hepatectomy 2 (2.4%) 1 (12.5%)  
 Left extended hepatectomy 2 (2.4%) 0 (0%)  
 Right trisectionectomy 2 (2.4%) 0 (0%)  
 Left trisectionectomy 1 (1.2%) 0 (0%)  
 Right hepatectomy + caudate 26 (31.7%) 1 (12.5%)  
 Right extended hepatectomy + caudate 7 (8.5%) 0 (0%)  
 Left hepatectomy + caudate 12 (14.6%) 3 (37.5%)  
 Left extended hepatectomy + caudate 5 (6.1%) 0 (0%)  
 Right trisectionectomy + caudate 17 (20.7%) 2 (25%)  
 Blood vessel reconstruction 22 (26.8%) 0 (0%) 0.210
 Portal vein reconstruction 17 (20.7%) 0 (0%) 0.339
 Hepatic artery reconstruction 5 (6.1%) 0 (0%) 1.000
 Patients with postoperative complications 46 (56.1%) 6 (75%) 0.510
 Renal complications 6 (7.3%) 3 (37.5%) 0.036a
  Urinary tract infection 1 (1.2%) 1 (12.5%) 0.418
  Renal failure 5 (6.1%) 2 (25%) 0.225
Patients with complications of grade IIIA or above 28 (34.1%) 4 (50%) 0.612
 Grade IIIA 24 (29.3%) 3 (37.5%) 0.936
 Grade IIIB 14 (17.1%) 1 (12.5%) 1.000
 Grade IVA 6 (7.3%) 1 (12.5%) 1.000
 Grade IVB 0 (0%) 0 (0%) ///
 Grade V 7 (8.5%) 4 (50%) 0.004a
In-hospital mortality 7 (8.5%) 4 (50%) 0.004a
30-day mortality 5 (6.1%) 2 (25%) 0.225
90-day mortality 8 (9.8%) 4 (50%) 0.008a
Hospital stay (days) 20.0 (6–93) 27.5 (10–214) 0.228
Pattern of recurrence    0.394
 No recurrence 31 (37.8%) 5 (62.5%)  
 Intrahepatic recurrence 7 (8.5%) 0 (0%)  
 Extrahepatic recurrence 22 (26.8%) 2 (25%)  
 Intrahepatic and extrahepatic recurrence 22 (26.8%) 1 (12.5%)  
Time to recurrence (months) 16.7 (1.2–218.3) 11.6 (1.1–24.4) 0.311
Follow-up duration (months) 21.6 (0.4–218.3) 4.1 (0.3–26.6) 0.008a
Resection margin    1.000
 Not involved 44 (53.7%) 4 (50%)  
 Involved 38 (46.3%) 4 (50%)  
Invasion of major branch of portal or hepatic vein    1.000
 No 70 (85.4%) 7 (87.5%)  
 Yes 12 (14.6%) 1 (12.5%)  
Microvascular invasion    0.429
 Absent 55 (67.1%) 7 (87.5%)  
 Present 27 (32.9%) 1 (12.5%)  
Number of lymph node metastasis 0.0 (0–25) 0.0 (0–3) 0.891
Klatskin staging    0.208
 I 12 (15.0%) 0 (0%)  
 II 25 (31.3%) 3 (37.5%)  
 IIIA 2 (2.5%) 1 (12.5%)  
 IIIB 26 (32.5%) 4 (50%)  
 IVA 12 (15.0%) 0 (0%)  
 IVB 3 (3.8%) 0 (0%)  
  1. Data are shown as number of patient (percent) or median (range)
  2. astatistically significant